You are not currently logged in.
Access JSTOR through your library or other institution:
Intra-Abdominal Anaerobic Infections: Bacteriology and Therapeutic Potential of Newer Antimicrobial Carbapenem, Fluoroquinolone, and Desfluoroquinolone Therapeutic Agents
Ellie J. C. Goldstein
Clinical Infectious Diseases
Vol. 35, Supplement 1. 2001: An Anaerobe Odyssey: A Celebration of Dr. Sydney M. Finegold's 80th Birthday (Sep. 1, 2002), pp. S106-S111
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4462171
Page Count: 6
You can always find the topics here!Topics: Anaerobic bacteria, Infections, Antimicrobials, Bacteremia, Appendicitis, Aerobic bacteria, Species, Bacteroides fragilis, Abscesses, Medical treatment
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Intra-abdominal infections are biphasic, synergistic processes with early peritonitis and bacteremia due to aerobes and a later abscess component due to anaerobes. Although Bacteroides fragilis is the most commonly recognized pathogen, other anaerobes, including other members of the B. fragilis-group species, are major components of infection. Anaerobic bacteremia is often associated with an intra-abdominal source. New antimicrobial agents with anaerobic activity are in various stages of development for the therapy of intra-abdominal infections. The in vitro activity and the currently available sparse clinical data are reviewed for a new carbapenem (ertapenem), several fluoroquinolones (trovafloxacin, moxifloxacin, and gemifloxacin), and a desfluoroquinolone (BMS-284756).
Clinical Infectious Diseases © 2002 Oxford University Press